| Autor: |
Shergalis AG; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Marin VL; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Rhee DY; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Senaweera S; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., McCloud RL; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Ronau JA; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Hutchins CW; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., McLoughlin S; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Woller KR; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Warder SE; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Vasudevan A; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States., Reitsma JM; Drug Discovery Science & Technology, AbbVie Inc, North Chicago, Illinois 60064, United States. |
| Abstrakt: |
Molecular glues (MGs) are monovalent small molecules that induce an interaction between proteins (native or non-native partners) by altering the protein-protein interaction (PPI) interface toward a higher-affinity state. Enhancing the PPI between a protein and E3 ubiquitin ligase can lead to degradation of the partnering protein. Over the past decade, retrospective studies of clinical drugs identified that immunomodulatory drugs (e.g., thalidomide and analogues) and indisulam exhibit a molecular glue effect by driving the interaction between non-native substrates to CRBN and DCAF15 ligases, respectively. Ensuing reports of phenotypic screens focused on MG discovery have suggested that these molecules may be more common than initially anticipated. However, prospective discovery of MGs remains challenging. Thus, expanding the repertoire of MGs will enhance our understanding of principles for prospective design. Herein, we report the results of a CRISPR/Cas9 knockout screen of over 1000 ligases and ubiquitin proteasome system components in a BRD4 degradation assay with a JQ1-based monovalent degrader, compound 1a . We identified DCAF16, a substrate recognition component of the Cul4 ligase complex, as essential for compound activity, and we demonstrate that compound 1a drives the interaction between DCAF16 and BRD2/4 to promote target degradation. Taken together, our data suggest that compound 1a functions as an MG degrader between BRD2/4 and DCAF16 and provides a foundation for further mechanistic dissection to advance prospective MG discovery. |
